Human trials of universal flu vaccine begin

Clinical trials of a new vaccine that could protect against multiple types of flu are beginning at Oxford University. If successful, the ‘universal’ flu injection would transform the way we vaccinate against influenza and could offer immunity to a bird flu pandemic.

Current vaccines are only effective against certain strains of flu. New formulations have to be developed every year according to which types of flu are thought likely to be circulating that winter.

‘This approach to influenza vaccination is unsatisfactory for use against seasonal influenza, and of little use when new types of flu begin to infect humans from birds,’ says Dr Sarah Gilbert of the Jenner Institute, University of Oxford.

‘It leaves manufacturers with a few months to produce the necessary stocks, the vaccine has to be administered to at-risk populations within a short time window, and those receiving the injection will all have to be vaccinated again the following year.

’Existing flu vaccines work by inducing protective antibodies to proteins on the outer surface of the influenza virus. These proteins differ between strains and change over time, so each vaccine only works against a specific strain.

The Oxford scientists led by Dr Gilbert are taking a new approach. They have developed a novel vaccine that targets internal proteins essential to the flu virus that change very little over time or between strains.

‘By targeting the internal proteins of the virus, we can come up with a universal flu jab,’ explains Dr Gilbert. ‘The same vaccine would work against all seasonal flu and protect against bird flu.’

Such a universal vaccine would not change from year to year, removing the need for annual immunisations. All ages could receive the injection at any time of year, and manufacturers would be able to produce supplies continuously at a sufficient level.

‘Children would be protected, we’d see economic benefits through reduced sickness in people of working age, and the elderly, who respond less well to vaccination, would be better off through lack of exposure to flu,’ explains Dr Gilbert.

In the Phase I clinical trial, 12 healthy volunteers are receiving the single injection of the new vaccine. Their immune response will then be monitored over time. Should this trial be successful, further clinical trials will be necessary before the vaccine can be approved. The research is funded by the Wellcome Trust.

The vaccine developed by Dr Gilbert and colleagues induces T cells, part of the body’s immune system, to kill any cells infected by the flu virus, so controlling the infection. The body maintains a low-level T cell response to flu from previous flu infections which the vaccine should boost to levels high enough to protect against subsequent infection.

Provided by Oxford University

Related stories:

Whooping cough cases on the rise in Midwest
An underreported, often misdiagnosed disease that people think affects only young children is drawing concern from national health officials and has recently struck hospital workers, closed schools in the Midwest and kept multiple health departments busy sending out alerts.
Fall babies: Born to wheeze?
It is said that timing is everything, and that certainly appears to be true for autumn infants. Children who are born four months before the height of cold and flu season have a greater risk of developing childhood asthma than children born at any other time of year, according to new research.
Scientists fight stem rust UG99 before it becomes a threat
(PhysOrg.com) -- Wheat breeders and plant pathologists at Montana State University are part of a global effort to develop varieties of wheat resistant to a new fungus. UG99, a stem rust strain that was first discovered in Africa and is slowly creeping towards the United States, could be devastating to Montana's wheat industry.
1918 Spanish flu records could hold the key to solving future pandemics
Ninety years after Australian scientists began their race to stop the spread of Spanish flu in Australia, University of Melbourne researchers are hoping records from the 1918 epidemic may hold the key to preventing future deadly pandemic outbreaks.
Flu shots may cut risk of blood clots forming in veins
Flu shots may reduce the risk of blood clots forming in veins by 26 percent, according to research presented at the American Heart Association's Scientific Sessions 2008.
Flu shot protects kids -- even during years with a bad vaccine match
Children who receive all recommended flu vaccine appear to be less likely to catch the respiratory virus that the CDC estimates hospitalizes 20,000 children every year.
Vaccinating family members offers important flu protection to newborns
Vaccinating new mothers and other family members against influenza before their newborns leave the hospital creates a "cocooning effect" that may shelter unprotected children from the flu, a virus that can be life-threatening to infants, according to researchers at Duke Children's Hospital.
Bird flu vaccine protects people and pets
A single vaccine could be used to protect chickens, cats and humans against deadly flu pandemics, according to an article published in the November issue of the Journal of General Virology. The vaccine protects birds and mammals against different flu strains and can even be given to birds while they are still in their eggs, allowing the mass vaccination of wild birds.

News discussion:

Medicine & Health news